Jci_page_head_homepage_01 Jci_page_head_homepage_02
Nicolas Leuenberger, Sylvain Pradervand, Walter Wahli
Published in Volume 119, Issue 10
J Clin Invest. 2009; 119(10):3138–3148 doi:10.1172/JCI39019
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 7
PPARα protects against estrogen-mediated hepatoxicity in females.

(A and B) Female PPARα-null and WT mice treated (black bars) or not treated (white bars) for 5 days with EE2. (C and D) Female PPARα-null and WT mice were treated for 5 days with EE2, with (black bars) or without (white bars) fenofibrate. (A and C) Hepatic Cyp7b1 and C6 mRNA levels were measured by QPCR and normalized to the 36B4 expression level. (B and D) Plasma bilirubin concentration. In AD, values are presented as mean ± SEM (n = 4). *P ≤ 0.05; **P ≤ 0.01. (E) Schematic representation of the PPARα-induced repression of Cyp7b1 in females. Sumoylation of PPARα promotes interaction with GABPs and HDACs, leading to DNA methylation by Dnmt3 and the displacement of Sp1 from its methylated core binding site. Removal of PPARα in female mice promotes the removal of the repression complex, which leads to Cyp7b1 stimulation. (F) Schematic representation of the protective effect of PPARα against estrogen-mediated inflammation and hepatotoxicity in females (F). αH3-K9 ac, αhistone 3 acetylated at Lys9; αH3-K9 tri-me, αhistone 3 trimethylated at Lys9.